Case Study

How A Leading Global Pharmaceutical Company Accelerated Enrollment In MDD And PTSD Study

Source: Trialbee AB
GettyImages-1319976569 ps


A large, global pharmaceutical sponsor launched a study to increase their knowledge around potential biomarkers for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). Recruitment for the study proved challenging for a variety of reasons. The study itself required participants to stay in the clinic for 24-hour periods. During these 24-hour periods, male and female patients were both present, a situation that made participation more difficult for female patients suffering from PTSD stemming from trauma that involved a male. Unlike other studies, this program was not researching a new therapy, nor was the sponsor able to offer financial compensation to participants. Finally, the potential study participant population was already limited to patients living within the geographic areas connected with only four clinical trial sites.

Find out more in the available case study.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader